As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Millions of dollars in a new $32.6 billion state budget proposal could allow for the return of GLP-1 coverage for some state employees.

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...

Employers are buying into these programs to satisfy worker demand for coverage of GLP-1s such as Wegovy, Zepbound and Saxenda. Others incorporate the PBM offerings into their employee health ...

That these treatments are helping people curb their eating should be no surprise: that is exactly what they are meant to do, by mimicking the satiety hormone GLP-1 (see “How they work”, below).

For pharma R&D, the expected ROI was 5.9% in 2024, up from 2023’s 4.1%. Of note is the role that GLP-1 therapies played in that increase, with the average return dropping to 3.8% when the drug ...

A review of randomized clinical trials found 33 occurrences of suicide-related behaviors with GLP-1s vs 27 for placebo. Data showed no outcome differences based on diabetes status or type of GLP-1 ...